

June 18, 2021

To whom it may concern:

Company Name Corporate Representative	TOHO HOLDINGS CO., LTD. Atsushi Udoh, President and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Launch of 3 Ingredients/ 6 Products of Generic Drugs for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has launched 3 ingredients/ 6 products of generic drugs today on June 18, 2021 as below.

New products list

Classes	Product Name	Original Brand Name
Insomnia treatment	ESZOPICLONE Tablets 1mg/2mg/3mg "KMP"	Lunesta®Tablets 1mg/2mg/3mg
Persistent AT1 receptor blocker / persistent Ca antagonist combination drug	ZiMlo COMBINATION TABLETS LD/HD "TOWA"	ZACRAS®Combination Tablets LD&HD
Phosphodiesterase-5 inhibitor	TADALAFIL TABLETS 20mgAD	Adcirca®Tablets 20mg